Campbell & CO Investment Adviser LLC Takes Position in Omnicell, Inc. $OMCL

Key Points

• Campbell & CO Investment Adviser LLC acquired 63,921 shares of Omnicell, Inc., valued at approximately $2.2 million, representing about 0.14% of the company's stock.
• Recent analyst upgrades for Omnicell include Wells Fargo raising the price target from $37.00 to $40.00, indicating a positive outlook for the stock.
• Omnicell reported an EPS of $0.45 for the last quarter, exceeding analysts' expectations and showing a 5.0% increase in revenue year-over-year.

Campbell & CO Investment Adviser LLC acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 63,921 shares of the company's stock, valued at approximately $2,235,000. Campbell & CO Investment Adviser LLC owned approximately 0.14% of Omnicell as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in OMCL. Mariner LLC lifted its position in shares of Omnicell by 16.1% in the fourth quarter. Mariner LLC now owns 9,075 shares of the company's stock worth $404,000 after buying an additional 1,261 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after buying an additional 394,820 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Omnicell by 5.9% in the fourth quarter. MetLife Investment Management LLC now owns 27,821 shares of the company's stock worth $1,239,000 after buying an additional 1,541 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Omnicell by 8.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 44,206 shares of the company's stock worth $1,969,000 after buying an additional 3,323 shares in the last quarter. Finally, Johnson Financial Group Inc. purchased a new stake in shares of Omnicell in the fourth quarter worth about $37,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Trading Up 0.2%

Shares of OMCL traded up $0.05 during mid-day trading on Thursday, reaching $33.28. 347,117 shares of the company's stock traded hands, compared to its average volume of 568,363. The stock has a market cap of $1.53 billion, a P/E ratio of 66.56, a P/E/G ratio of 7.15 and a beta of 0.78. The stock's 50-day moving average is $29.98 and its two-hundred day moving average is $31.68. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Research analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on OMCL. Benchmark decreased their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Piper Sandler reduced their price objective on Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Bank of America boosted their price objective on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Wells Fargo & Company boosted their price objective on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Finally, Wall Street Zen cut Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Omnicell presently has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.